- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02848144
Pediatric Immune Response to Infectious Shock (PedIRIS)
Infectious shocks are associated with high mortality rates (20-40%). Anti-inflammatory strategies based on the postulate that mortality related to sepsis is mainly due to an overwhelming pro-inflammatory immune response have failed. Some patients surviving this initial phase can develop immune dysfunctions because the compensatory mechanisms become deleterious when they persist over time. The persistence of immunosuppression at day 3 or 5 is independently associated with more nosocomial infections and higher mortality rate. The clinical and laboratory evidence for sepsis induced immunosuppression have been recently reviewed by Hotchkiss et al. Apoptosis-induced depletion of immune effector and blood studies from septic patients showed decreased production of pro-inflammatory cytokines, decreased HLA-DR expression, increased percentage of regulatory T cells, and increased production of programmed cell death (PD)-1. Some small positive phase 2 trials of biomarker guided immune enhancing agents granulocyte-macrophage colony stimulating factor (GM-CSF) and interferon γ (IFN γ) have been reported.
There are insufficient data showing that such an immunosuppression exists in children. Only one study performed in children with organ dysfunctions admitted to pediatric intensive care unit (PICU), showed that 34% of them developed immunosuppression. This study was performed on a heterogeneous population and immunological analyses were limited. Therefore, there is a crucial need of studies on septic patients with matched controls to provide more evidence that the same paradigm exists in children. The collaboration of laboratories with a high level of experience in this domain, and a clinical unit with a high potential of recruitment of children with severe infectious shock should allow us to perform the first prospective study specifically done in children with infectious shock.
The main hypothesis is that children with severe infectious shock developed sepsis-induced immunosuppression as shown in adults. This will be assessed by the expression of HLA-DR on monocytes' surface. We make the hypothesis that children who become immunosuppressed are more prone to develop secondary nosocomial infectious and stayed longer in PICU and in hospital.
Children aged from 1 month to 17 years, admitted to PICU at HFME Lyon-Bron are eligible if they have the criteria for severe sepsis or septic shock, defined by the "Surviving Sepsis Campaign 2012" or those of Toxic Shock Syndrome (TSS) (definitions of CDC - Center for Disease Control). An information leaflet will be issued to parents and children / adolescents and they will be informed of their right to object to the search. Are provided as part of this research:
- Immunological measures (mHLA -DR) in three stages: in the first 48 hours, between D3/5 and D7/9. The volume of collected blood will not exceed 2.4 ml / kg.
- The collection of nosocomial infections and status at D30 A control group of patients hospitalized for surgery without sepsis or toxic shock criteria will be recruited in the same hospital by ICU investigators and matched for age. Similarly controls will be given oral and written information and they will have the opportunity to deny inclusion. They will have the same exams as the first group of patients.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
-
Lyon, Francie
- Hospices Civils De Lyon
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria Infectious shock group:
- Children aged from 1 month to <18 years
- Diagnosis of severe infectious shock at PICU or within the first 24 hours following PICU admission: severe sepsis or septic shock, defined by Surviving Sepsis Campaign 2012, or Toxic Shock Syndrome, defined by CDC criteria.
Inclusion Criteria Control group:
- Healthy children aged matched to cases
- Hospitalized for an elective surgery (dental, ENT, maxillofacial, urologic, hernia surgery, neurosurgery without massive hemorrhage)
- Without any criteria of infection.
Exclusion Criteria (both groups):
- Chronic inflammatory disease;
- Immunodeficiency;
- Long-term corticosteroids;
- Ongoing immunosuppressive treatment;
- Transplanted patients;
- Tumors, hematological diseases;
- No health insurance coverage;
- Refusal to participate (from parents and/or patient) or inability to understand information.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Základní věda
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Jiný: Children with infectious shock
Children aged from 1 month to <18 years.
In 3 stratified groups : <2 years, 2-8 years, and >8 years.
About one third of the patients are expected in each age-group.
|
|
Jiný: Control group: healthy children
Healthy children aged-matched to cases (same stratification group, about 20 per age group); They will be hospitalized for an elective surgery (dental, ENT, maxillofacial, urologic, hernia surgery, neurosurgery without massive hemorrhage) and without any infection.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
proportion of patients with a mHLA-DR level <30%
Časové okno: up to Day 9
|
mHLA-DR is measured by flow cytometry
|
up to Day 9
|
proportion of patients with a mHLA-DR level significantly lower than healthy children.
Časové okno: in the pre-operative period
|
mHLA-DR is measured by flow cytometry
|
in the pre-operative period
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
total lymphocytes
Časové okno: Day 1
|
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
|
Day 1
|
total lymphocytes
Časové okno: between Day 3 and day 5
|
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
|
between Day 3 and day 5
|
total lymphocytes
Časové okno: between Day 7 and day 9
|
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
|
between Day 7 and day 9
|
levels of CD4+
Časové okno: Day 1
|
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
|
Day 1
|
levels of CD4+
Časové okno: between Day 3 and day 5
|
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
|
between Day 3 and day 5
|
levels of CD4+
Časové okno: between Day 7 and day 9
|
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
|
between Day 7 and day 9
|
levels of CD25+
Časové okno: day 1
|
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
|
day 1
|
levels of CD25+
Časové okno: between Day 3 and day 5
|
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
|
between Day 3 and day 5
|
levels of CD25+
Časové okno: between Day 7 and day 9
|
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
|
between Day 7 and day 9
|
levels of T lymphocytes (Treg)
Časové okno: Day 1
|
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
|
Day 1
|
levels of T lymphocytes (Treg)
Časové okno: between Day 3 and day 5
|
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
|
between Day 3 and day 5
|
levels of T lymphocytes (Treg)
Časové okno: between Day 7 and day 9
|
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
|
between Day 7 and day 9
|
dosage of cytokines
Časové okno: Day 1
|
Day 1
|
|
dosage of cytokines
Časové okno: between Day 3 and day 5
|
between Day 3 and day 5
|
|
dosage of cytokines
Časové okno: between Day 7 and day 9
|
between Day 7 and day 9
|
|
Number of nosocomial infections
Časové okno: up to Day 30
|
up to Day 30
|
|
Type of nosocomial infections
Časové okno: up to Day 30
|
bacteremia, ventilator-associated pneumonia, urinary tract infection, other sites.
|
up to Day 30
|
Mortality
Časové okno: up to Day 30
|
up to Day 30
|
|
Length of vasoactive treatments
Časové okno: up to Day 30
|
up to Day 30
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Etienne JAVOUHEY, Hospices Civils De Lyon
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 69HCL16_0478
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na vzorky krve
-
Hillel Yaffe Medical CenterNeznámý
-
National Marrow Donor ProgramDokončenoLymfom | Myelodysplastické syndromy | LeukémieSpojené státy
-
ExThera Medical Europe BVExThera Medical Corporation; Vivantes Clinic NeuköllnNáborInfekce krevního řečištěFrancie, Německo, Holandsko, Rakousko, Belgie, Itálie, Polsko, Španělsko, Spojené království
-
University Hospital, RouenZatím nenabírámeŽloutenka typu B | Hepatitida C | AIDSFrancie
-
Careggi HospitalUniversity of FlorenceNáborSepse | Syndrom systémové zánětlivé odpovědi | Závažné onemocnění | Akutní poškození ledvinItálie
-
Assistance Publique - Hôpitaux de ParisFilière des Maladies Rares Abdomino-THOraciques : FIMATHOStaženoVrozená brániční kýla | Gastroschíza | OmfalokélaFrancie
-
BHI Therapeutic SciencesNeznámýAkutní ischemická mrtviceSpojené státy
-
Kirby InstituteNáborŽloutenka typu BAustrálie
-
Bursa Uludag UniversitesiZápis na pozvánkuRakovina tlustého střeva | Chemoterapeutický efekt | Orální mukositida | Role sestryKrocan
-
Smiths Medical, ASD, Inc.Dokončeno